March 21st 2024
GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Balstilimab for patients with metastatic cervical cancer
September 15th 2021Results of a phase 2 study demonstrate that the anti-programmed death-1 (PD-1) antibody balstilimab from Agenus Inc. provides meaningful and durable clinical activity in patients with previously treated, recurrent/metastatic cervical cancer.
Read More
FDA accepts pembrolizumab as single agent for treatment of advanced endometrial cancer
August 16th 2021The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Read More
Adapting cervical cancer screening to decreasing HPV infection rates
July 12th 2021For cervical cancer screening, human papillomavirus (HPV)–based screening modalities detect significantly more abnormal cervical cells than traditional liquid-based cytology (LBC) approaches, according to a study in JAMA Network Open.
Read More
Nemvaleukin monotherapy and with pembrolizumab for ovarian cancer
June 18th 2021Nemvaleukin alfa (Alkermes) was mostly well tolerated and indicated antitumor activity as both monotherapy and in combination with pembrolizumab among patients with advanced solid tumors, according to study results presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held virtually from June 4-8.
Read More
Subcutaneous nemvaleukin dosing for advanced ovarian cancer
June 11th 2021“I believe in combinatorial immunotherapeutic regimens in an attempt to increase efficacy and durability of response,” said principal investigator Omid Hamid, MD, director of clinical research and immunotherapy at The Angeles Clinic and Research Institute in Los Angeles, an affiliate of Cedars-Sinai Medical Center.
Read More
Laparoscopy better than imaging for accurate staging in locally advanced cervical cancer
January 11th 2021While no difference was shown in disease-free survival rates between surgical and non-surgical staging methods, laparoscopy benefits patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer. Surgical staging also has a cancer-specific survival benefit, according to a study published in the International Journal of Gynecological Cancers.
Read More
Improved survival rate in patients with advanced endometrial cancer
December 31st 2020Pembrolizumab plus lenvatinib induced a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with advanced endometrial cancer after prior systemic therapy in the phase 3 KEYNOTE-775/Study 309 trial.
Read More
Sexual health after cancer treatment
December 4th 2020The vast majority of cancer survivors reported that they experience sexual side effects after chemotherapy, radiation and other cancer treatments according to the results of a survey presented at the annual meeting of the American Society for Radiation Oncology.
Read More
Novel engineered cytokine plus pembrolizumab to treat ovarian cancer
November 24th 2020Heavily pretreated ovarian cancer patients who received a combination therapy of a novel engineered interleukin-2 (IL-2) cytokine plus pembrolizumab achieved an acceptable safety profile, according to a small cohort of an ongoing phase 1/2 trial.
Read More
Recurrence of high-grade cervical dysplasia
September 18th 2020Women with high-grade cervical dysplasia are much less likely to have recurrence after primary conization if they undergo laser conization than a loop electrosurgical excision procedure (LEEP), according to a 5-year follow-up study.
Read More